Experience of Professor Wan Donggui in treating triple negative breast cancer from phlegm
ZHANG Jing1 LUO Chufan1 ZHOU Xin1 WAN Donggui2▲
1.Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100029, China;
2.Internal Oncology Department of Integrated Chinese and Western Medicine, China-Janpan Friendship Hospital, Beijing 100029, China
Abstract：Triple-negative breast cancer is a difficult and hot spot in clinical research. At present, Western medicine lacks targeted treatment methods, and traditional Chinese medicine has certain characteristics and advantages. Professor Wan Donggui has been practicing medicine for more than 30 years, and has opened a special disease clinic for triple-negative breast cancer for 8 years. She has accumulated rich clinical experience, and is good at treating triple-negative breast cancer from phlegm. She has created a special disease prescription for the prevention and treatment of recurrence and metastasis of triple-negative breast cancer, “Louci Sanjie Fang”, which has been applied in clinical practice for many years and has achieved satisfactory results. Professor Wan Donggui thinks that endogenous phlegm-turbidity is an important part of the occurrence and development of triple-negative breast cancer, phlegm-dampness is a common constitution of triple-negative breast cancer, phlegm-turbid coagulation is the main cause of recurrence and metastasis of triple-negative breast cancer, so the main therapeutic principle is dissipating phlegm to remove mass, treating form depression and deficiency, dispersing the stagnated liver-energy and invigorating the spleen, regulating qi-flowing for eliminating phlegm. Meanwhile, she pays attention to guiding medicinal herb, makes good use of the drugs for dredging mammary collaterals, ventilating lung qi for dissipating phlegm, dispelling wind and dredging channel, in order to eliminate the source of phlegm, improve biased physique constitution, and prevent development and transmission.
张静1 罗楚凡1 周馨1 万冬桂2▲. 万冬桂教授从痰论治三阴性乳腺癌经验[J]. 中国医药导报, 2021, 18(9): 156-159.
ZHANG Jing1 LUO Chufan1 ZHOU Xin1 WAN Donggui2▲. Experience of Professor Wan Donggui in treating triple negative breast cancer from phlegm. 中国医药导报, 2021, 18(9): 156-159.
[1] 马云飞，孙旭，念家云，等.三阴性乳腺癌的中西医治疗现状[J].中国肿瘤临床与康复，2017，24（3）：366-369.
[2] Xiao W，Zheng S，Yang A，et al. Breast cancer subtypes and the risk of distant metastasis at initial diagnosis a population-based study [J]. Cancer Manag Rese，2018， 10：5329-5338.
[3] Kaur P，Nagaraja GM，Zheng H，et al. A mouse model for triple-negative breast cancer tumor-initiating cells（TNBC-TICs）exhibits similar aggressive phenotype to the human disease [J]. BMC cancer，2012，12：120.
[4] 张萍，徐兵河，马飞，等.晚期三阴性乳腺癌临床特征及生存分析[J].中华肿瘤杂志，2011，33（5）：381-384.
[5] Wang Y，Li JW，Qin YN，et al. Clinical Observation on the Effect of Chinese Medicine-“TCM Formula” Intervention on Recurrence and Metastasis of Triple Negative Breast Cancer [J]. Complement Ther Med，2020，52：102456.
[6] 王庆才.恶性肿瘤从痰论治初探[J].辽宁中医杂志，1996， 23（5）：209-211.
[7] 中华中医药学会.中医体质分类与判定[J].中华养生保健：上半月，2009（9）：38-39.
[8] 黄羚，江媚，刘宁远，等.三阴性乳腺癌患者中医体质类型分析及其与TOP2A基因表达的相关性[J].中国中医药信息杂志，2015，22（1）：14-17.
[9] 郭鹏，邹志东.北京社区乳腺癌高危人群中医体质分布特点研究[J].河北中医，2017，39（6）：839-843.
[10] 王萌，叶倩瑜，张明星.自拟化痰散结方对三阴乳腺癌新辅助化疗增敏作用的临床研究[J].广西中医药，2019， 42（6）：4-7.
[11] 程培育，王皓，韩冬，等.温阳化痰法联合化疗治疗晚期三阴性乳腺癌临床研究[J].中华中医药杂志，2019，34（7）：3128-3131.
[12] 王俊涛，尹怡，李晓婷，等.益肾化痰法对乳腺癌骨转移患者血液PTHrP、FGF-β、BSP水平的影响及作用机制分析[J].中医药学报，2019，47（1）：85-88.
[13] 袁斯远，刘金民.α细辛醚药理学研究进展[J].中西医结合心脑血管病杂志，2020，18（8）：1247-1249.
[14] 杨小金，邓艾平，王奕，等.石菖蒲化学成分及药理作用研究进展[J].内蒙古中医药，2017，36（19）：132-133.
[15] Sun J，Meng H，Yao L，et al. Germline mutations in cancers susceptibility genes in a large series of unselected breast cancer patients [J]. Clin Cancer Res，2017，23（20）：6113-6119.
[16] 王志慧.理气化痰汤辅助化疗治疗乳腺癌临床观察[J].中医药临床杂志，2018，30（6）：1117-1119.
[17] 沈霞平.疏肝消痰汤联合EC-T化疗治疗乳腺癌术后54例[J].中国中医药科技，2019，26（4）：574-575.
[18] Caparica R，Lambertini M，de Azambuja E. How I treat metastatic triple-negative breast cancer [J]. ESMO Open， 2019，4（Suppl 2）：e504.
[19] Steward L，Conant L，Gao F，et al. Predictive factors and patterns of recurrence in patients with triple negative breast cancer [J]. Ann Surg Oncol，2014，21（7）：2165-2171.
[20] 牛晓雨，王璐，孙放，等.山慈菇水煎剂对乳腺癌MDA-MB-231细胞的影响[J].中成药，2018，40（1）：197-200.
[21] 刘银花，钟世军，曾涛，等.山慈菇提取液对小鼠4T1乳腺癌细胞抑制作用机制的研究[J].湖北农业科学，2016， 55（1）：134-137.
[22] 郭淳，龚永杰，孙放，等.山慈菇水煎剂对人乳腺癌T-47D细胞增殖和迁移的影响[J].中医学报，2017，32（10）：1832-1835.
[23] 李雪莲，李智，黄芊，等.山慈菇介导VEGF-A血管生成抑制乳腺癌细胞上皮-间质转化的实验研究[J].中国医师杂志，2019，21（11）：1658-1662.
[24] 童晔玲，杨锋，戴关海，等.猫爪草总皂苷对非小细胞肺癌A549细胞裸鼠移植瘤生长及EGFR、MMP-9表达的影响[J].中华中医药学刊，2015，33（1）：24-26，179-181.
[25] 尹春萍，樊龙昌，张立冬，等.猫爪草皂苷抑制乳腺癌的机制研究[J].中国医院药学杂志，2008，28（2）：93-96.
[26] 王会敏，何柯新，尚新宇，等.猫爪草多糖的理化性质及其对ANA-1细胞的免疫调节作用[J].热带医学杂志，2018，18（7）：23-27，32.
2021, Vol. 18 
京公网安备 11010502046598号